Low Vitamin D Levels Linked to Increased Risk of Retinal Vein Occlusion

Eyes in the serum: what a half-million patient dataset actually says

Half a million electronic health records later, and the retina-versus-vitamin D question finally has numbers attached to it. According to a propensity-score-matched cohort study published in Scientific Reports, adults aged 50 and older with serum 25-hydroxyvitamin D below 20 ng/mL showed a meaningfully higher risk of retinal vein occlusion than matched peers sitting comfortably at or above 30 ng/mL. The sample is enormous — 454,432 patients drawn from the TriNetX Global Collaborative Network, each cohort ballooning to 227,216 after 1:1 matching. For a micronutrient that the supplement aisle has been hawking for everything from bones to mood, that kind of dataset is not nothing.

So is deficiency the mechanism? Or is it the next correlation masquerading as one?

The hazard ratios, stripped of hype

The headline hazard ratios from the study are worth reading once without the supplement industry's commentary:

• Incident retinal vein occlusion: HR 1.58 (95% CI 1.28–1.96)
• Central RVO: HR 1.53 (95% CI 1.14–2.05)
• Branch RVO: HR 1.65 (95% CI 1.24–2.21)
• All-cause blindness: HR 1.85 (95% CI 1.56–2.20)

Those are not subtle elevations. The blindness endpoint carries the widest absolute risk, which lines up with RVO being one of the commonest vascular causes of vision loss in older adults. Estimates held up across sensitivity analyses, including a parallel run using the vitamin D insufficiency range (20–30 ng/mL), and the pattern persisted across subgroups. In propensity-matched observational data, that kind of consistency is the best argument you get short of a randomized trial.

Why the laboratory eye stays open

Here is the part the marketing copy will skip: the authors are explicit that causality cannot be inferred. RVO is driven by atherosclerosis, hypertension, thrombophilia, and a stack of vascular comorbidities that also track with low serum 25(OH)D. Propensity matching adjusts for the measured ones and leaves the unmeasured ones free to ride along. The mechanism — endothelial dysfunction, renin-angiotensin dysregulation, impaired angiogenesis — is plausible, but plausible is not proven.

For the fortification and micronutrient-policy crowd, the practical reading is straightforward. A 20 ng/mL floor for "deficiency" is conservative by Endocrine Society standards and generous by the IOM cutoff of 12 ng/mL for risk at the population level. If a large, well-matched cohort keeps showing vascular-eye risk clustered under that 20 ng/mL line, the argument for lifting population serum 25(OH)D through food fortification rather than individual supplementation gets a little more empirical weight. Not a verdict — a data point worth tracking.

The blunt laboratory verdict: correlation, strong and reproducible; mechanism, biologically reasonable; causation, still missing. Anyone selling vitamin D as eye protection on the strength of one observational cohort should be asked to wait for the trial.